1. Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC). Issue 1 (1st January 2021) Authors: Wang, Wenguang; Gan, Zhilu; Liu, Qiang; Yan, Shenshen; Mulati, Rexiti; Wang, Yujie Journal: Bioengineered Issue: Volume 12:Issue 1(2021) Page Start: 2957 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗